Vaccine Production Core

疫苗生产核心

• 批准号: 7127923
• 负责人: NORMAN L LETVIN
• 金额: $ 121.41万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-07-14 至 2012-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7127923
• 关键词: AIDS vaccines; Adenoviridae; HIV infections; Macaca mulatta; Mycobacterium; Vesiculovirus; biomedical facility; biotechnology; chemokine; cooperative study; drug design /synthesis /production; human immunodeficiency virus 1; immunomodulators; live vaccine; microorganism immunology; recombinant proteins; toll like receptor; vaccine development; vector vaccine

The work of the Vaccine Production Core encompasses efforts in three inter-related areas: live, recombinant vector development; novel adjuvant development; and protein production. The efforts that will be pursued in vector and adjuvant development by this CHAVI group will be described. A rationale for pursuing each technology, the work accomplished to date in developing that technology, and the immediate plans for further development of that technology will be described. This CHAVI group will begin to advance the most promising of these technologies into human clinical testing as early as the second year of the funding period. The protein production component of this core will serve the Haynes RO1, the Shaw SLG project, the Sodroski SLG project, and the Structural Biology Core D. Specifically, we will pursue work in the following areas: 1. Live, recombinant vector development a. Recombinant chimeric adenovirus b. Recombinant mycobacteria c. Recombinant vesicular stomatitis virus 2. Novel adjuvant development a. Polymers b. Chemoattractant cytokines c. TLR agonists 3. Recombinant protein production

疫苗生产核心的工作涵盖三个相互关联的领域：活疫苗、 重组载体开发；新型佐剂的开发；和蛋白质生产。将描述该 CHAVI 小组将在载体和佐剂开发方面所做的努力。将描述追求每项技术的理由、迄今为止开发该技术所完成的工作以及进一步开发该技术的近期计划。 CHAVI 小组最早将在资助期的第二年开始将这些技术中最有前途的技术推进到人体临床测试中。该核心的蛋白质生产组件将服务于 Haynes RO1、Shaw SLG 项目、Sodroski SLG 项目和结构生物学核心 D 项目。具体来说，我们将在以下领域开展工作： 1. 活重组载体开发 一个。重组嵌合腺病毒 b.重组分枝杆菌 c.重组水泡性口炎病毒 2. 新型佐剂开发 一个。聚合物 b.趋化细胞因子 c. TLR激动剂 3. 重组蛋白生产